Resilience care is a company.
Key people at Resilience care.
Resilience care was founded by Celine Lazorthes (Co-Founder & Co-CEO).
Resilience care was founded by Celine Lazorthes (Co-Founder & Co-CEO).
Key people at Resilience care.
Resilience Care is a French healthtech startup founded in 2021 that develops a digital remote patient monitoring platform and mobile app primarily for oncology patients, with expansions into psychiatry and gastroenterology. It serves cancer patients and healthcare professionals by personalizing care pathways, managing treatment side effects, and improving quality of life through data-driven insights and therapeutic education.[2][4] Deployed in over 90 medical centers supporting more than 10,000 patients, the company raised $25 million in funding to scale internationally, riding the wave of digital health innovation for equitable, patient-centered medicine.[2][4]
The platform, a Class IIa medical device, combines a patient-facing mobile app for self-care with a professional dashboard for real-time monitoring, humanizing care and addressing gaps in traditional oncology pathways.[4] This positions Resilience Care as a growth-stage player in personalized medicine, backed by partnerships like Gustave Roussy, Europe's leading cancer center.[2][4]
Resilience Care was founded in February 2021 in Paris by Céline Lazorthes and Jonathan Benhamou, co-founders and co-CEOs, emerging from a partnership with Gustave Roussy to tackle inequities in cancer care access.[2][4] The idea stemmed from urgency around geography and inequality limiting quality care, starting with oncology remote monitoring to personalize and humanize patient journeys.[2][4]
Early traction came quickly: by the funding announcement, it was live in over 90 centers with 10,000+ patients, validating the model through real-world deployment and positive clinical impacts.[4] This clinician-backed origin—rooted in a top cancer institute—provided immediate credibility and momentum for expansion beyond oncology.[2]
Resilience Care capitalizes on the remote patient monitoring (RPM) trend, accelerated by post-COVID digital health adoption and demand for personalized medicine amid rising chronic disease burdens like cancer.[2][4] Timing aligns with regulatory support for Class IIa devices and AI/data integration in healthcare, making scalable RPM viable as hospitals face staffing shortages and care inequities.[4]
Market forces favor it: Europe's oncology market grows with aging populations, while funding (e.g., $25M round) reflects investor bets on healthtech amid €2.5B+ AUM firms like Cathay Innovation targeting cross-border scale.[4] It influences the ecosystem by partnering with elite centers like Gustave Roussy, setting standards for patient-empowered care and bridging clinical research with real-world deployment.[2][4]
Resilience Care is poised for aggressive expansion post-$25M raise, targeting international markets in oncology, psychiatry, and gastroenterology while deepening RPM integrations.[4] Trends like AI-enhanced personalization and value-based care will propel growth, potentially tripling patient reach as remote solutions become standard.
Its influence may evolve from niche oncology innovator to broad personalized medicine leader, challenging siloed care models—ultimately making equitable, tech-driven health accessible beyond privilege, as envisioned from its founding urgency.[2]
